Daré Bioscience (DARE) Stock Forecast, Price Target & Predictions
DARE Stock Forecast
Daré Bioscience stock forecast is as follows: an average price target of $12.00 (represents a 276.18% upside from DARE’s last price of $3.19) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
DARE Price Target
The average price target for Daré Bioscience (DARE) is $12.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential 276.18% upside from DARE's last price of $3.19.
DARE Analyst Ratings
According to 1 Wall Street analysts, Daré Bioscience's rating consensus is 'Buy'. The analyst rating breakdown for DARE stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Daré Bioscience Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 24, 2024 | Douglas Tsao | H.C. Wainwright | $12.00 | $3.50 | 242.86% | 276.18% |
The latest Daré Bioscience stock forecast, released on Oct 24, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $12.00, which represents a 242.86% increase from the stock price at the time of the forecast ($3.50), and a 276.18% increase from DARE last price ($3.19).
Daré Bioscience Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $12.00 | $12.00 |
| Last Closing Price | $3.19 | $3.19 | $3.19 |
| Upside/Downside | -100.00% | 276.18% | 276.18% |
In the current month, the average price target of Daré Bioscience stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Daré Bioscience's last price of $3.19. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 24, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Daré Bioscience's last stock rating was published by H.C. Wainwright on Oct 24, 2024. The company gave DARE a "Buy" rating, the same as its previous rate.
Daré Bioscience Financial Forecast
Daré Bioscience Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 17 | Mar 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $1.00M | - | - | - | $10.00M | - | - | - | - | - | - | - | $1.19M | $47.00K |
| Avg Forecast | $8.10M | $600.00K | $600.00K | $600.00K | $1.33M | $1.03M | $7.86M | $260.50K | $2.38M | $733.33K | $1.10M | $1.67M | $7.96M | $10.00M | $362.75K | $1.67M | $5.72M | $520.00K | $645.00K | $304.33K | $277.67K | $1.37K | $442.37K |
| High Forecast | $8.10M | $600.00K | $600.00K | $600.00K | $1.33M | $1.03M | $7.86M | $260.75K | $2.55M | $733.50K | $1.10M | $1.67M | $7.96M | $10.00M | $362.75K | $1.67M | $5.72M | $624.00K | $645.00K | $304.33K | $277.67K | $1.64K | $530.84K |
| Low Forecast | $8.10M | $600.00K | $600.00K | $600.00K | $1.33M | $1.03M | $7.86M | $260.25K | $2.19M | $733.17K | $1.10M | $1.67M | $7.96M | $10.00M | $362.75K | $1.67M | $5.72M | $416.00K | $645.00K | $304.33K | $277.67K | $1.09K | $353.89K |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 9 | 9 | 10 | 10 | 20 | 10 | 10 | 10 | 20 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.36% | - | - | - | 1.00% | - | - | - | - | - | - | - | 871.35% | 0.11% |
Daré Bioscience's average Quarter revenue forecast for Dec 23 based on 3 analysts is $2.38M, with a low forecast of $2.19M, and a high forecast of $2.55M. DARE's average Quarter revenue forecast represents a 137.63% increase compared to the company's last Quarter revenue of $1.00M (Sep 23).
Daré Bioscience EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 17 | Mar 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 9 | 9 | 10 | 10 | 20 | 10 | 10 | 10 | 20 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-8.40M | $-8.99M | $-8.38M | $-7.14M | $389.64K | $-8.40M | $-9.54M | $-12.66M | $-7.32M | $-8.43M | $-7.57M | $-7.11M | $-5.48M | $-2.42M |
| Avg Forecast | $1.62M | $120.00K | $120.00K | $120.00K | $266.67K | $207.00K | $1.57M | $52.10K | $475.25K | $146.67K | $220.00K | $333.33K | $1.59M | $2.00M | $72.55K | $333.33K | $1.14M | $-9.89M | $129.00K | $60.87K | $55.53K | $-6.18M | $-22.75M |
| High Forecast | $1.62M | $120.00K | $120.00K | $120.00K | $266.67K | $207.00K | $1.57M | $52.15K | $510.29K | $146.70K | $220.00K | $333.33K | $1.59M | $2.00M | $72.55K | $333.33K | $1.14M | $-7.91M | $129.00K | $60.87K | $55.53K | $-4.95M | $-18.20M |
| Low Forecast | $1.62M | $120.00K | $120.00K | $120.00K | $266.67K | $207.00K | $1.57M | $52.05K | $438.02K | $146.63K | $220.00K | $333.33K | $1.59M | $2.00M | $72.55K | $333.33K | $1.14M | $-11.87M | $129.00K | $60.87K | $55.53K | $-7.42M | $-27.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | -57.25% | -40.86% | -25.15% | -4.48% | 0.19% | -115.72% | -28.61% | -11.06% | 0.74% | -65.39% | -124.38% | -128.07% | 0.89% | 0.11% |
1 analysts predict DARE's average Quarter EBITDA for Sep 22 to be $1.59M, with a high of $1.59M and a low of $1.59M. This is 308.58% upper than Daré Bioscience's previous annual EBITDA (Jun 22) of $389.64K.
Daré Bioscience Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 17 | Mar 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 9 | 9 | 10 | 10 | 20 | 10 | 10 | 10 | 20 | 10 |
| Net Income | - | - | - | - | - | - | - | - | - | $-8.30M | $-8.76M | $-7.70M | $-6.90M | $414.00K | $-8.40M | $-9.54M | $-12.67M | $-7.32M | $-8.44M | $-7.58M | $-7.12M | $-6.34M | $-2.91M |
| Avg Forecast | $-2.39M | $-4.48M | $-3.80M | $-5.55M | $-4.52M | $-5.85M | $-332.84K | $-6.14M | $-9.22M | $-10.04M | $-10.07M | $-10.24M | $-11.87M | $-6.44M | $-14.49M | $-14.85M | $-12.97M | $-8.99M | $-13.39M | $-17.29M | $-15.26M | $-7.16M | $-27.43M |
| High Forecast | $-2.39M | $-4.48M | $-3.80M | $-4.61M | $-3.56M | $-5.85M | $-332.84K | $-6.14M | $-4.61M | $-10.04M | $-10.07M | $-10.24M | $-11.87M | $-6.44M | $-14.49M | $-14.85M | $-12.97M | $-7.19M | $-13.39M | $-17.29M | $-15.26M | $-5.73M | $-21.94M |
| Low Forecast | $-2.39M | $-4.48M | $-3.80M | $-6.49M | $-5.48M | $-5.85M | $-332.84K | $-6.14M | $-14.59M | $-10.04M | $-10.07M | $-10.24M | $-11.87M | $-6.44M | $-14.49M | $-14.85M | $-12.97M | $-10.79M | $-13.39M | $-17.29M | $-15.26M | $-8.59M | $-32.91M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.83% | 0.87% | 0.75% | 0.58% | -0.06% | 0.58% | 0.64% | 0.98% | 0.81% | 0.63% | 0.44% | 0.47% | 0.89% | 0.11% |
Daré Bioscience's average Quarter net income forecast for Sep 22 is $-11.87M, with a range of $-11.87M to $-11.87M. DARE's average Quarter net income forecast represents a -2966.38% decrease compared to the company's last Quarter net income of $414.00K (Jun 22).
Daré Bioscience SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 17 | Mar 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 9 | 9 | 10 | 10 | 20 | 10 | 10 | 10 | 20 | 10 |
| SG&A | - | - | - | - | - | - | - | - | - | $2.70M | $2.92M | $3.36M | $2.68M | $2.82M | $2.59M | $2.43M | $2.24M | $1.97M | $1.80M | $1.38M | $1.58M | $3.59M | $1.51M |
| Avg Forecast | $13.67M | $1.01M | $1.01M | $1.01M | $2.25M | $1.75M | $13.26M | $439.57K | $4.01M | $1.24M | $1.86M | $2.81M | $13.41M | $16.85M | $611.12K | $2.81M | $9.64M | $876.03K | $1.09M | $512.70K | $467.78K | $2.30K | $745.25K |
| High Forecast | $13.67M | $1.01M | $1.01M | $1.01M | $2.25M | $1.75M | $13.26M | $439.99K | $4.31M | $1.24M | $1.86M | $2.81M | $13.41M | $16.85M | $611.12K | $2.81M | $9.64M | $1.05M | $1.09M | $512.70K | $467.78K | $2.76K | $894.30K |
| Low Forecast | $13.67M | $1.01M | $1.01M | $1.01M | $2.25M | $1.75M | $13.26M | $439.15K | $3.70M | $1.24M | $1.86M | $2.81M | $13.41M | $16.85M | $611.12K | $2.81M | $9.64M | $700.83K | $1.09M | $512.70K | $467.78K | $1.84K | $596.20K |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.18% | 1.57% | 1.20% | 0.20% | 0.17% | 4.25% | 0.86% | 0.23% | 2.24% | 1.66% | 2.69% | 3.37% | 1556.86% | 2.03% |
Daré Bioscience's average Quarter SG&A projection for Dec 23 is $4.01M, based on 3 Wall Street analysts, with a range of $3.70M to $4.31M. The forecast indicates a 48.69% rise compared to DARE last annual SG&A of $2.70M (Sep 23).
Daré Bioscience EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 17 | Mar 14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 9 | 9 | 10 | 10 | 20 | 10 | 10 | 10 | 20 | 10 |
| EPS | - | - | - | - | - | - | - | - | - | $-91.15 | $-0.10 | $-0.09 | $-0.08 | - | $-0.10 | $-0.13 | $-0.18 | $-0.16 | $-0.27 | $-0.24 | $-0.27 | $-2.20 | $-37.00 |
| Avg Forecast | $-0.28 | $-0.53 | $-0.45 | $-0.65 | $-0.53 | $-0.69 | $-0.04 | $-0.72 | $-1.08 | $-1.18 | $-1.18 | $-1.20 | $-1.40 | $-0.76 | $-1.71 | $-1.75 | $-1.53 | $-2.76 | $-1.58 | $-2.04 | $-1.80 | $-3.50 | $-27.95 |
| High Forecast | $-0.28 | $-0.53 | $-0.45 | $-0.54 | $-0.42 | $-0.69 | $-0.04 | $-0.72 | $-0.54 | $-1.18 | $-1.18 | $-1.20 | $-1.40 | $-0.76 | $-1.71 | $-1.75 | $-1.53 | $-2.76 | $-1.58 | $-2.04 | $-1.80 | $-2.80 | $-22.36 |
| Low Forecast | $-0.28 | $-0.53 | $-0.45 | $-0.76 | $-0.64 | $-0.69 | $-0.04 | $-0.72 | $-1.71 | $-1.18 | $-1.18 | $-1.20 | $-1.40 | $-0.76 | $-1.71 | $-1.75 | $-1.53 | $-2.76 | $-1.58 | $-2.04 | $-1.80 | $-4.20 | $-33.54 |
| Surprise % | - | - | - | - | - | - | - | - | - | 77.51% | 0.08% | 0.08% | 0.06% | -0.01% | 0.06% | 0.07% | 0.12% | 0.06% | 0.17% | 0.12% | 0.15% | 0.63% | 1.32% |
According to 1 Wall Street analysts, Daré Bioscience's projected average Quarter EPS for Sep 22 is $-1.40, with a low estimate of $-1.40 and a high estimate of $-1.40. This represents a -28671.43% decrease compared to DARE previous annual EPS of - (Jun 22).
Daré Bioscience Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SNSE | Sensei Biotherapeutics | $0.48 | $5.50 | 1045.83% | Buy |
| PASG | Passage Bio | $0.67 | $6.00 | 795.52% | Buy |
| BDTX | Black Diamond Therapeutics | $2.50 | $20.00 | 700.00% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.40 | $10.00 | 614.29% | Buy |
| DARE | Daré Bioscience | $3.19 | $12.00 | 276.18% | Buy |
| NXTC | NextCure | $0.90 | $3.00 | 233.33% | Buy |
| SLS | SELLAS Life Sciences Group | $0.88 | $2.80 | 218.18% | Buy |
| EYPT | EyePoint Pharmaceuticals | $8.02 | $22.00 | 174.31% | Buy |
| KZR | Kezar Life Sciences | $6.52 | $17.50 | 168.40% | Buy |
| NUVB | Nuvation Bio | $2.81 | $7.00 | 149.11% | Buy |
| ALEC | Alector | $1.89 | $4.00 | 111.64% | Buy |
| XBIO | Xenetic Biosciences | $4.07 | $4.00 | -1.72% |